Epigral

₹1278.8 18 | 1.4%

WEBSITE BSE:543332 NSE : EPIGRAL 10 May, 16:01

Market Cap ₹5313 Cr.

Stock P/E 27.1

P/B 4.2

Current Price ₹1278.8

Book Value ₹ 301.8

Face Value 10

52W High ₹1438.8

Dividend Yield 0.39%

52W Low ₹ 870

Edit Ratio

Epigral Research see more...

Overview Inc. Year: 2007Industry: Chemicals

Meghmani Finechem Ltd manufactures and sells chlor-alkali and its derivatives in India. The enterprise offers caustic soda, chlorine, hydrogen, caustic potash, chloromethanes, and hydrogen peroxide. It serves alumina, textile, crop protection, refineries, pharmaceutical, paper and pulp, dyes and pigments, cleaning soap and detergent, refrigerant gases, and different industries. The business enterprise was established in 2007 and is based totally in Ahmedabad, India.

Epigral Share Price

New

Volume

Price

Price: NSE50 DMA200 DMAVolume

Quarterly Price

Quarterly Monthly

Show Value Show %

Peer Comparison

Epigral Quarterly Results

#(Fig in Cr.)	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Dec 2023	Mar 2024
Net Sales	340	422	499	533	556	538	562	455	472	525
Other Income	2	-0	2	2	2	-0	5	2	2	2
Total Income	342	422	501	535	557	538	567	456	474	526
Total Expenditure	239	281	324	345	375	371	408	360	349	369
Operating Profit	103	141	177	189	182	166	159	97	125	157
Interest	10	10	12	11	14	21	19	18	20	14
Depreciation	22	22	21	22	26	31	30	31	31	30
Exceptional Income / Expenses	0	0	0	0	0	0	0	0	0	0
Profit Before Tax	71	109	144	156	142	114	110	48	74	113
Provision for Tax	24	39	45	49	50	37	33	16	25	36
Profit After Tax	47	70	99	108	92	77	77	32	49	77
Adjustments	0	0	0	0	-0	-0	-0	-0	-0	1
Profit After Adjustments	47	70	99	108	92	77	77	32	49	77
Adjusted Earnings Per Share	11.3	16.8	23.8	25.9	22	18.6	18.5	7.6	11.8	18.6

Epigral Profit & Loss

#(Fig in Cr.)	Mar 2021	Mar 2022	Mar 2023	TTM
Net Sales	829	1551	2188	2014
Other Income	7	8	9	11
Total Income	836	1559	2198	2023
Total Expenditure	567	1041	1499	1486
Operating Profit	269	518	698	538
Interest	34	48	67	71
Depreciation	74	86	109	122
Exceptional Income / Expenses	0	0	0	0
Profit Before Tax	161	383	522	345
Provision for Tax	60	131	169	110
Profit After Tax	101	253	353	235
Adjustments	0	0	0	1
Profit After Adjustments	101	253	353	235
Adjusted Earnings Per Share	24.3	60.8	85	56.5

Growth Rates

#	1 Year	3 Year	5 Year	10 Year
Sales CAGR	41%	0%	0%	0%
Operating Profit CAGR	35%	0%	0%	0%
PAT CAGR	40%	0%	0%	0%

#	1 Year	3 Year	5 Year	10 Year
Share Price CAGR	33%	NA%	NA%	NA%
ROE Average	39%	34%	34%	34%
ROCE Average	32%	26%	26%	26%

Epigral Balance Sheet

#(Fig in Cr.)	Mar 2021	Mar 2022	Mar 2023
Shareholder's Funds	684	726	1069
Minority's Interest	0	0	0
Borrowings	340	768	545
Other Non-Current Liabilities	35	97	171
Total Current Liabilities	389	532	648
Total Liabilities	1449	2124	2432
Fixed Assets	1102	1068	1804
Other Non-Current Assets	165	609	209
Total Current Assets	181	447	419
Total Assets	1449	2124	2432

Epigral Cash Flow

#(Fig in Cr.)	Mar 2021	Mar 2022	Mar 2023
Opening Cash & Cash Equivalents	0	1	25
Cash Flow from Operating Activities	229	284	626
Cash Flow from Investing Activities	-197	-455	-437
Cash Flow from Financing Activities	-32	195	-200
Net Cash Inflow / Outflow	1	24	-11
Closing Cash & Cash Equivalent	1	25	14

Epigral Ratios

#	Mar 2021	Mar 2022	Mar 2023
Earnings Per Share (Rs)	24.27	60.84	85.03
CEPS(Rs)	41.97	81.51	111.25
DPS(Rs)	0	0	5
Book NAV/Share(Rs)	113.88	174.72	257.3
Core EBITDA Margin(%)	30.5	31.74	29.72
EBIT Margin(%)	22.79	26.9	25.42
Pre Tax Margin(%)	18.77	23.88	22.54
PAT Margin (%)	11.77	15.75	15.24
Cash Profit Margin (%)	20.35	21.1	19.94
ROA(%)	6.96	14.15	15.51
ROE(%)	21.31	42.16	39.36
ROCE(%)	15.97	29.4	32.2
Receivable days	50.62	42.65	33.28
Inventory Days	22.99	23.66	28.81
Payable days	69.2	38.64	32.46
PER(x)	0	16.01	11.09
Price/Book(x)	0	5.57	3.67
Dividend Yield(%)	0	0	0.53
EV/Net Sales(x)	0.95	3.23	2.18
EV/Core EBITDA(x)	2.94	9.68	6.85
Net Sales Growth(%)	0	87.18	41.1
EBIT Growth(%)	0	121.21	36.43
PAT Growth(%)	0	150.68	39.76
EPS Growth(%)	0	150.7	39.76
Debt/Equity(x)	0.79	1.36	0.82
Current Ratio(x)	0.47	0.84	0.65
Quick Ratio(x)	0.33	0.55	0.32
Interest Cover(x)	5.68	8.91	8.82
Total Debt/Mcap(x)	0	0.24	0.22

Epigral Shareholding Pattern

#	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024
Promoter	71.18	71.18	71.11	71.12	71.21	71.34	71.37	71.38	71.38	71.49
FII	1.16	1.02	1.38	1.4	1.15	1.2	1.17	1.15	1.18	1.36
DII	0	0.49	0.24	0.22	0.2	0.06	0.06	0.07	0.08	0.05
Public	27.65	27.31	27.27	27.26	27.45	27.39	27.4	27.41	27.36	27.1
Others	0.01	0	0	0	0	0	0	0	0	0
Total	100	100	100	100	100	100	100	100	100	100

#	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024
Promoter	2.96	2.96	2.95	2.96	2.96	2.96	2.97	2.97	2.97	2.97
FII	0.05	0.04	0.06	0.06	0.05	0.05	0.05	0.05	0.05	0.06
DII	0	0.02	0.01	0.01	0.01	0	0	0	0	0
Public	1.15	1.13	1.13	1.13	1.14	1.14	1.14	1.14	1.14	1.13
Others	0	0	0	0	0	0	0	0	0	0
Total	4.16	4.16	4.16	4.16	4.16	4.16	4.16	4.16	4.16	4.16

Pros

Company has a good return on equity (ROE) track record: 3 Years ROE 34%
Debtor days have improved from 38.64 to 32.46days.
Company has reduced debt.

Cons

Stock is trading at 4.2 times its book value.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.